A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.

被引：4
|
作者：
Hyman, David Michael
Brana, Irene
Spreafico, Anna
Schram, Alison M.
Pandya, Naimish B.
Hoffman, Kimberly
Hallet, Robin
Giblin, Patricia
Anido, Judit
Ruano, Isabel Huber
Wasserman, Robert
Magram, Jeanne
Siu, Lillian L.
Tabernero, Josep
Seoane, Joan
Baselga, Jose
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] UHN Princess Margaret Hosp, Cambridge, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Northern Biol Inc, Toronto, ON, Canada
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2602
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
    Colin D. Weekes
    Muralidhar Beeram
    Anthony W. Tolcher
    Kyriakos P. Papadopoulos
    Lia Gore
    Priti Hegde
    Yan Xin
    Ron Yu
    L. Mason Shih
    Hong Xiang
    Rainer K. Brachmann
    Amita Patnaik
    Investigational New Drugs, 2014, 32 : 653 - 660
  • [32] A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors
    Weiss, Glen J.
    Luke, Jason J.
    Falchook, Gerald
    Eroglu, Zeynep
    Wang, Judy
    Hamilton, Erika
    Hecht, J. Randolph
    LoRusso, Patricia
    Eder, Joseph Paul
    Hughes, Lorraine
    Wang, Jing
    Running, Kelli
    McEachern, Kristen
    Bobilev, Dmitri
    Ribas, Antoni
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [33] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Patnaik, Amita
    Kang, S. Peter
    Rasco, Drew
    Papadopoulos, Kyriakos P.
    Elassaiss-Schaap, Jeroen
    Beeram, Muralidhar
    Drengler, Ronald
    Chen, Cong
    Smith, Lon
    Espino, Guillermo
    Gergich, Kevin
    Delgado, Liliana
    Daud, Adil
    Lindia, Jill A.
    Li, Xiaoyun Nicole
    Pierce, Robert H.
    Yearley, Jennifer H.
    Wu, Dianna
    Laterza, Omar
    Lehnert, Manfred
    Iannone, Robert
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
  • [34] Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.
    Gomez-Roca, Carlos Alberto
    Cassier, Philippe Alexandre
    Italiano, Antoine
    Cannarile, Michael
    Ries, Carola
    Brillouet, Anne
    Mueller, Claudia
    Jegg, Anna-Maria
    Meneses-Lorente, Georgina
    Baehner, Monika
    Abiraj, Keelara
    Loirat, Delphine
    Toulmonde, Maud
    D'Angelo, Sandra P.
    Weber, Kristy
    Campone, Mario
    Ruettinger, Dominik
    Blay, Jean-Yves
    Delord, Jean-Pierre
    Le Tourneau, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors
    Wang, Chong
    He, Xiaohui
    Zhou, Bo
    Li, Jing
    Li, Bohua
    Qian, Weizhu
    Hou, Sheng
    Wang, Hao
    Shi, Yuankai
    Guo, Yajun
    MABS, 2011, 3 (01) : 67 - 75
  • [36] Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.
    Desai, Jayesh
    Voskoboynik, Mark
    Markman, Ben
    Hou, Jeannie
    Zeng, Dewan
    Meniawy, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors
    Glisson, B. S.
    Leidner, R.
    Ferris, R. L.
    Powderly, J.
    Rizvi, N.
    Norton, J. D.
    Burton, J.
    Lanasa, M. C.
    Patel, S. P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
    Colin D. Weekes
    Lee S. Rosen
    Anna Capasso
    Kit Man Wong
    Weilan Ye
    Maria Anderson
    Bruce McCall
    Jill Fredrickson
    Eric Wakshull
    Steve Eppler
    Quyen Shon-Nguyen
    Rupal Desai
    Mahrukh Huseni
    Priti S. Hegde
    Tony Pourmohamad
    Ina Rhee
    Alberto Bessudo
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 339 - 351
  • [39] Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
    Weekes, Colin D.
    Rosen, Lee S.
    Capasso, Anna
    Wong, Kit Man
    Ye, Weilan
    Anderson, Maria
    McCall, Bruce
    Fredrickson, Jill
    Wakshull, Eric
    Eppler, Steve
    Quyen Shon-Nguyen
    Desai, Rupal
    Huseni, Mahrukh
    Hegde, Priti S.
    Pourmohamad, Tony
    Rhee, Ina
    Bessudo, Alberto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 339 - 351
  • [40] Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
    Falchook, Gerald Steven
    Desai, Jayesh
    Leitch, Ian M.
    Goldman, Jonathan Wade
    Wheler, Jennifer J.
    Fu, Siqing
    Kurzrock, Razelle
    Baldwin, Megan
    Rosen, Lee S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345